Skip to main content
An official website of the United States government
NIH Websites Are Changing
Per Executive Order 14434, federal agencies are now using "Super Intelligence" (SI) in place of "Artificial Intelligence" (AI). You may see both terms across NIH content during this transition.

actinium Ac 225 rosopatamab tetraxetan

A radioimmunoconjugate consisting of a humanized monoclonal antibody directed against prostate specific membrane antigen (PSMA) labeled with the alpha particle-emitting radioisotope actinium Ac-225, with potential antineoplastic activity. Upon administration, actinium Ac 225 rosopatamab tetraxetan binds to the extracellular domain of PSMA with high affinity, thereby delivering alpha radiation to PSMA expressing cells. PSMA, a type II membrane protein expressed in all types of prostatic tissues, is often overexpressed in tumor cells.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:Ac 225 MOAB J591
Ac 225 monoclonal antibody J591
actinium Ac-225 anti-prostate-specific membrane antigen monoclonal antibody J591
actinium Ac-225 anti-PSMA monoclonal antibody J591
Abbreviation:225Ac-J591
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search